The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anti Epilepsy Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Antiepileptic drugs (AEDs) are commonly termed as anticonvulsants or antiseizure drugs, which are used in symptomatic treatment of epileptic seizures. The epileptic seizures show recurring episodes and occur due to wrong signal sent by nerve cells to the brain. Antiepileptic drugs also act as mood stabilizers and also used in the treatment of bipolar disorders or neuropathic pain.
The global Anti Epilepsy Drugs market size is expected to reach US$ 4175.7 million by 2029, growing at a CAGR of 2.1% from 2023 to 2029. The market is mainly driven by the significant applications of Anti Epilepsy Drugs in various end use industries. The expanding demands from the Partial and Generalized, are propelling Anti Epilepsy Drugs market. First Generation AEDs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Second Generation AEDs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti Epilepsy Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti Epilepsy Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti Epilepsy Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti Epilepsy Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti Epilepsy Drugs covered in this report include Abbott Laboratories, Cephalon, Sunovion Pharmaceuticals, Bausch Health, Sanofi, UCB Pharma, GlaxoSmithKline, Johnson & Johnson and Novartis, etc.
The global Anti Epilepsy Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Cephalon
Sunovion Pharmaceuticals
Bausch Health
Sanofi
UCB Pharma
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Global Anti Epilepsy Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti Epilepsy Drugs market, Segment by Type:
First Generation AEDs
Second Generation AEDs
Global Anti Epilepsy Drugs market, by Application
Partial
Generalized
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anti Epilepsy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anti Epilepsy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Antiepileptic drugs (AEDs) are commonly termed as anticonvulsants or antiseizure drugs, which are used in symptomatic treatment of epileptic seizures. The epileptic seizures show recurring episodes and occur due to wrong signal sent by nerve cells to the brain. Antiepileptic drugs also act as mood stabilizers and also used in the treatment of bipolar disorders or neuropathic pain.
The global Anti Epilepsy Drugs market size is expected to reach US$ 4175.7 million by 2029, growing at a CAGR of 2.1% from 2023 to 2029. The market is mainly driven by the significant applications of Anti Epilepsy Drugs in various end use industries. The expanding demands from the Partial and Generalized, are propelling Anti Epilepsy Drugs market. First Generation AEDs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Second Generation AEDs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti Epilepsy Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti Epilepsy Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti Epilepsy Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti Epilepsy Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti Epilepsy Drugs covered in this report include Abbott Laboratories, Cephalon, Sunovion Pharmaceuticals, Bausch Health, Sanofi, UCB Pharma, GlaxoSmithKline, Johnson & Johnson and Novartis, etc.
The global Anti Epilepsy Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
Cephalon
Sunovion Pharmaceuticals
Bausch Health
Sanofi
UCB Pharma
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Global Anti Epilepsy Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti Epilepsy Drugs market, Segment by Type:
First Generation AEDs
Second Generation AEDs
Global Anti Epilepsy Drugs market, by Application
Partial
Generalized
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anti Epilepsy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anti Epilepsy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Anti Epilepsy Drugs Market Overview
1.1 Anti Epilepsy Drugs Product Overview
1.2 Anti Epilepsy Drugs Market Segment by Type
1.2.1 First Generation AEDs
1.2.2 Second Generation AEDs
1.3 Global Anti Epilepsy Drugs Market Size by Type
1.3.1 Global Anti Epilepsy Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Anti Epilepsy Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Anti Epilepsy Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Anti Epilepsy Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Anti Epilepsy Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Anti Epilepsy Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Anti Epilepsy Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Anti Epilepsy Drugs Sales Breakdown by Type (2018-2023)
2 Global Anti Epilepsy Drugs Market Competition by Company
2.1 Global Top Players by Anti Epilepsy Drugs Sales (2018-2023)
2.2 Global Top Players by Anti Epilepsy Drugs Revenue (2018-2023)
2.3 Global Top Players by Anti Epilepsy Drugs Price (2018-2023)
2.4 Global Top Manufacturers Anti Epilepsy Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Anti Epilepsy Drugs Market Competitive Situation and Trends
2.5.1 Anti Epilepsy Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Anti Epilepsy Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti Epilepsy Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Anti Epilepsy Drugs Market
2.8 Key Manufacturers Anti Epilepsy Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Anti Epilepsy Drugs Status and Outlook by Region
3.1 Global Anti Epilepsy Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Anti Epilepsy Drugs Historic Market Size by Region
3.2.1 Global Anti Epilepsy Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Anti Epilepsy Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Anti Epilepsy Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Anti Epilepsy Drugs Forecasted Market Size by Region
3.3.1 Global Anti Epilepsy Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Anti Epilepsy Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Anti Epilepsy Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Anti Epilepsy Drugs by Application
4.1 Anti Epilepsy Drugs Market Segment by Application
4.1.1 Partial
4.1.2 Generalized
4.2 Global Anti Epilepsy Drugs Market Size by Application
4.2.1 Global Anti Epilepsy Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Anti Epilepsy Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Anti Epilepsy Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Anti Epilepsy Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Anti Epilepsy Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Anti Epilepsy Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Anti Epilepsy Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Anti Epilepsy Drugs Sales Breakdown by Application (2018-2023)
5 North America Anti Epilepsy Drugs by Country
5.1 North America Anti Epilepsy Drugs Historic Market Size by Country
5.1.1 North America Anti Epilepsy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Anti Epilepsy Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Anti Epilepsy Drugs Sales in Value by Country (2018-2023)
5.2 North America Anti Epilepsy Drugs Forecasted Market Size by Country
5.2.1 North America Anti Epilepsy Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Anti Epilepsy Drugs Sales in Value by Country (2024-2029)
6 Europe Anti Epilepsy Drugs by Country
6.1 Europe Anti Epilepsy Drugs Historic Market Size by Country
6.1.1 Europe Anti Epilepsy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Anti Epilepsy Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Anti Epilepsy Drugs Sales in Value by Country (2018-2023)
6.2 Europe Anti Epilepsy Drugs Forecasted Market Size by Country
6.2.1 Europe Anti Epilepsy Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Anti Epilepsy Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Anti Epilepsy Drugs by Region
7.1 Asia-Pacific Anti Epilepsy Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Anti Epilepsy Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Anti Epilepsy Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Anti Epilepsy Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Anti Epilepsy Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Anti Epilepsy Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Anti Epilepsy Drugs Sales in Value by Region (2024-2029)
8 Latin America Anti Epilepsy Drugs by Country
8.1 Latin America Anti Epilepsy Drugs Historic Market Size by Country
8.1.1 Latin America Anti Epilepsy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Anti Epilepsy Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Anti Epilepsy Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Anti Epilepsy Drugs Forecasted Market Size by Country
8.2.1 Latin America Anti Epilepsy Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Anti Epilepsy Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Anti Epilepsy Drugs by Country
9.1 Middle East and Africa Anti Epilepsy Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Anti Epilepsy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Anti Epilepsy Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Anti Epilepsy Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Anti Epilepsy Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Anti Epilepsy Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Anti Epilepsy Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Company Information
10.1.2 Abbott Laboratories Introduction and Business Overview
10.1.3 Abbott Laboratories Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Abbott Laboratories Anti Epilepsy Drugs Products Offered
10.1.5 Abbott Laboratories Recent Development
10.2 Cephalon
10.2.1 Cephalon Company Information
10.2.2 Cephalon Introduction and Business Overview
10.2.3 Cephalon Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Cephalon Anti Epilepsy Drugs Products Offered
10.2.5 Cephalon Recent Development
10.3 Sunovion Pharmaceuticals
10.3.1 Sunovion Pharmaceuticals Company Information
10.3.2 Sunovion Pharmaceuticals Introduction and Business Overview
10.3.3 Sunovion Pharmaceuticals Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sunovion Pharmaceuticals Anti Epilepsy Drugs Products Offered
10.3.5 Sunovion Pharmaceuticals Recent Development
10.4 Bausch Health
10.4.1 Bausch Health Company Information
10.4.2 Bausch Health Introduction and Business Overview
10.4.3 Bausch Health Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Bausch Health Anti Epilepsy Drugs Products Offered
10.4.5 Bausch Health Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Introduction and Business Overview
10.5.3 Sanofi Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Anti Epilepsy Drugs Products Offered
10.5.5 Sanofi Recent Development
10.6 UCB Pharma
10.6.1 UCB Pharma Company Information
10.6.2 UCB Pharma Introduction and Business Overview
10.6.3 UCB Pharma Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 UCB Pharma Anti Epilepsy Drugs Products Offered
10.6.5 UCB Pharma Recent Development
10.7 GlaxoSmithKline
10.7.1 GlaxoSmithKline Company Information
10.7.2 GlaxoSmithKline Introduction and Business Overview
10.7.3 GlaxoSmithKline Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 GlaxoSmithKline Anti Epilepsy Drugs Products Offered
10.7.5 GlaxoSmithKline Recent Development
10.8 Johnson & Johnson
10.8.1 Johnson & Johnson Company Information
10.8.2 Johnson & Johnson Introduction and Business Overview
10.8.3 Johnson & Johnson Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Johnson & Johnson Anti Epilepsy Drugs Products Offered
10.8.5 Johnson & Johnson Recent Development
10.9 Novartis
10.9.1 Novartis Company Information
10.9.2 Novartis Introduction and Business Overview
10.9.3 Novartis Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Novartis Anti Epilepsy Drugs Products Offered
10.9.5 Novartis Recent Development
10.10 Pfizer
10.10.1 Pfizer Company Information
10.10.2 Pfizer Introduction and Business Overview
10.10.3 Pfizer Anti Epilepsy Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Pfizer Anti Epilepsy Drugs Products Offered
10.10.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Anti Epilepsy Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Anti Epilepsy Drugs Industrial Chain Analysis
11.4 Anti Epilepsy Drugs Market Dynamics
11.4.1 Anti Epilepsy Drugs Industry Trends
11.4.2 Anti Epilepsy Drugs Market Drivers
11.4.3 Anti Epilepsy Drugs Market Challenges
11.4.4 Anti Epilepsy Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Anti Epilepsy Drugs Distributors
12.3 Anti Epilepsy Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
